

# Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

## **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference**

Format: Podium presentation

Date: Tuesday, September 10, 2024

Time: 9:00 a.m. ET

## **Baird 2024 Global Healthcare Conference**

Format: Fireside chat

Date: Wednesday, September 11, 2024

Time: 10:50 a.m. ET

A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>, and will be available for replay following the event.

## **About Karyopharm Therapeutics**

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit [www.karyopharm.com](http://www.karyopharm.com), and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

SOURCE Karyopharm Therapeutics Inc.

For further information: Investors, Elhan Webb, CFA, Senior Vice President, Investor Relations, 617.658.0600 | [elhan.webb@karyopharm.com](mailto:elhan.webb@karyopharm.com); Media, David Rosen, Argot Partners, 646.461.6387, [david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

---

<https://investors.karyopharm.com/2024-09-03-Karyopharm-to-Participate-at-Upcoming-Investor-Conferences>